Zenagamtide

Zenagamtide
Clinical data
Other namesNN 9487; NN9487; NNC0487-0111
Identifiers
CAS Number

Amycretin/Zenagamtide (development code NN 9487) is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally. A subcutaneous injection formulation is being developed in parallel.

The drug's dual mechanism of action, which affects appetite regulation (through the GLP-1 receptor) and metabolism (through the amylin receptor), distinguishes it from existing weight loss medications. It contains two covalently linked peptides that are analogs of GLP-1 and amylin respectively. The oral formulation contains salcaprozate sodium (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate; SNAC) as a permeation enhancer.

Clinical trials

On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin.

In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks.

Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.

References

  1. ↑ Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (1 February 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity. 49 (3): 433–451. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497. PMC 11971045. PMID 38302593.
  2. ↑ Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug". MarketWatch. Retrieved 11 March 2024.
  3. ↑ Jamaluddin, Aqfan; Gorvin, Caroline M (21 March 2023). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. 70 (4). Bioscientifica: e230014. doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555. PMID 36943057.
  4. ↑ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists". Obesity Reviews. 25 (3) e13663. doi:10.1111/obr.13663. ISSN 1467-7881. PMID 37968541.
  5. ↑ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (March 2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists". Obesity Reviews. 25 (3) e13663. doi:10.1111/obr.13663. PMID 37968541.
  6. 1 2 Gasiorek A, Heydorn A, Kirkeby K, Key C, Toubro S, Schefe LH, et al. (September 2024). "Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study". Diabetologia. 67. Springer: S42–S43.
  7. 1 2 ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. 7 March 2024. Retrieved 13 March 2024.
  8. ↑ Clinical trial number NCT05369390 for "A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity" at ClinicalTrials.gov
  9. ↑ Clinical trial number NCT06049329 for "A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity" at ClinicalTrials.gov
  10. ↑ "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. 24 January 2025. Retrieved 29 January 2025.
  11. ↑ Clinical trial number NCT06064006 for "A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin" at ClinicalTrials.gov